Hypoxia-inducible Factor-1 (HIF-1): Pharmacological And Molecular Insights Into Its Role In Brain Protection
Funder
National Health and Medical Research Council
Funding Amount
$293,229.00
Summary
At present, there are no effective therapies for reducing brain damage which can occur after acute brain insults including birth asphyxia. This project aims to study whether increasing a naturally occurring protective protein (HIF) in the brain can minimize brain damage in a model of perinatal brain injury. We plan to validate HIF as a novel therapeutic target for reduce brain injury and promote brain repair processes.
Macfarlane Adaptive Changes In HIV-1 Subtype C Envelope Glycoproteins Contributing To Pathogenicity.
Funder
National Health and Medical Research Council
Funding Amount
$310,787.00
Summary
HIV exists as multiple subtypes. The most commonly studied is type B (B-HIV). B-HIV is common in developed countries, but accounts for only a small fraction of HIV infections worldwide. Type C HIV (C-HIV) in Africa and Asia accounts for the majority of infections worldwide, yet very little is known about how C-HIV causes AIDS. We aim to understand how C-HIV causes AIDS. This is critical for development of drugs and vaccines specifically designed for those who are most urgently need.
We discovered, characterised and commercialised Macrophage inhibitory cytokine-1 (MIC-1/GDF15) for human therapy. Its blood level predicts death from cancer, heart attack/stroke and other diseases. This study will add important information for understandg the actions of this important protein